Overview

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Status:
Completed

Trial end date:
2017-06-26

Target enrollment:

Participant gender:

Summary

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial hypercholesterolemia.

Phase:

Phase 1

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Collaborator:

Akcea Therapeutics

Treatments:

Riboflavin